000109059 001__ 109059
000109059 005__ 20230519145436.0
000109059 0247_ $$2doi$$a10.1016/j.pnpbp.2020.110207
000109059 0248_ $$2sideral$$a122480
000109059 037__ $$aART-2021-122480
000109059 041__ $$aeng
000109059 100__ $$0(orcid)0000-0002-7297-6104$$aSantabárbara, J.$$uUniversidad de Zaragoza
000109059 245__ $$aPrevalence of anxiety in the COVID-19 pandemic: An updated meta-analysis of community-based studies
000109059 260__ $$c2021
000109059 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109059 5203_ $$aBackground: The unprecedented worldwide crisis caused by the rapid spread of COVID-19 and the restrictive public health measures enforced by some countries to slow down its transmission have severely threatened the physical and mental wellbeing of communities globally.
Methods: We conducted a systematic review and meta-analysis to determine the prevalence of anxiety in the general population during the COVID-19 pandemic. Two researchers independently searched for cross-sectional community-based studies published between December 1, 2019 and August 23, 2020, using PubMed, WoS, Embase, and other sources (e.g., grey literature, manual search).
Results: Of 3049 records retrieved, 43 studies were included. These studies yielded an estimated overall prevalence of anxiety of 25%, which varied significantly across the different tools used to measure anxiety. Consistently reported risk factors for the development of anxiety included initial or peak phase of the outbreak, female sex, younger age, marriage, social isolation, unemployment and student status, financial hardship, low educational level, insufficient knowledge of COVID-19, epidemiological or clinical risk of disease and some lifestyle and personality variables.
Conclusions: As the overall global prevalence of anxiety disorders is estimated to be 7.3% normally, our results suggest that rates of anxiety in the general population could be more than 3 times higher during the COVID-19 pandemic. These findings suggest a substantial impact on mental health that should be targeted by individual and population-level strategies.
000109059 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/98-0103$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/97-1321E$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/94-1562$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/06-0617$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/03-0815$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/01-0255$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI-19-01874$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/G03-128$$9info:eu-repo/grantAgreement/ES/DGA-FEDER/B15-17R
000109059 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000109059 590__ $$a5.201$$b2021
000109059 592__ $$a1.37$$b2021
000109059 594__ $$a9.5$$b2021
000109059 591__ $$aCLINICAL NEUROLOGY$$b55 / 212 = 0.259$$c2021$$dQ2$$eT1
000109059 593__ $$aPharmacology$$c2021$$dQ1
000109059 591__ $$aPSYCHIATRY$$b55 / 157 = 0.35$$c2021$$dQ2$$eT2
000109059 593__ $$aBiological Psychiatry$$c2021$$dQ1
000109059 591__ $$aPHARMACOLOGY & PHARMACY$$b70 / 279 = 0.251$$c2021$$dQ2$$eT1
000109059 591__ $$aNEUROSCIENCES$$b85 / 275 = 0.309$$c2021$$dQ2$$eT1
000109059 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000109059 700__ $$0(orcid)0000-0003-1894-5531$$aLasheras, I.
000109059 700__ $$aLipnicki, D.M.
000109059 700__ $$aBueno-Notivol, J.
000109059 700__ $$aPérez-Moreno, M.
000109059 700__ $$0(orcid)0000-0002-3360-7015$$aLópez-Antón, R.$$uUniversidad de Zaragoza
000109059 700__ $$0(orcid)0000-0003-2284-7862$$aDe la Cámara, C.$$uUniversidad de Zaragoza
000109059 700__ $$0(orcid)0000-0002-9098-655X$$aLobo, A.$$uUniversidad de Zaragoza
000109059 700__ $$0(orcid)0000-0001-9822-6312$$aGracia-García, P.$$uUniversidad de Zaragoza
000109059 7102_ $$14009$$2730$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicología Básica
000109059 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000109059 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000109059 773__ $$g109 (2021), 461766 [14 pp]$$pProg. neuro-psychopharmacol. biol. psychiatry$$tPROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY$$x0278-5846
000109059 8564_ $$s851101$$uhttps://zaguan.unizar.es/record/109059/files/texto_completo.pdf$$yPostprint
000109059 8564_ $$s2231552$$uhttps://zaguan.unizar.es/record/109059/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000109059 909CO $$ooai:zaguan.unizar.es:109059$$particulos$$pdriver
000109059 951__ $$a2023-05-18-14:24:17
000109059 980__ $$aARTICLE